Table 1.
Patient characteristics within the most prevalent ependymal tumor classes
| EPN-PFB | PF-SE/E | EPN-ZFTA | |
|---|---|---|---|
| Number, n (%) | 56 (32.9) | 44 (25.9) | 19 (11.2) |
| Age, [y] median (range) | 39 (18-66) | 60 (29-81) | 37 (20-63) |
| Sex ratio | |||
| Male to female | ~1:1 | ~8:1 | ~2:1 |
| KPS, n (%) | |||
| <70 | 4 (11) | 9 (25) | 1 (12) |
| 70–80 | 11 (31) | 14 (39) | 2 (25) |
| 90–100 | 21 (58) | 13 (36) | 5 (63) |
| No data | 20 | 8 | 11 |
| Extent of surgery, n (%) | |||
| Subtotal | 18 (34) | 18 (45) | 2 (13) |
| Gross total | 35 (66) | 22 (55) | 13 (87) |
| No data | 3 | 4 | 4 |
| Adjuvant therapy, n (%) | |||
| None | 36 (67) | 35 (81) | 4 (25) |
| RT alone | 18 (33) | 8 (19) | 9 (56) |
| Chemotherapy alone | 0 (0) | 0 (0) | 0 (0) |
| RT + Chemotherapy | 0 (0) | 0 (0) | 3 (19) |
| No data | 2 | 1 | 3 |
| CNS WHO Grade, n (%) | |||
| 2 | 49 (88) | 41 (93) | 1 (5) |
| 3 | 7 (12) | 3 (7) | 18 (95) |
| Tumor location, n (%) | |||
| Supratentorial | 2 (4) | 2 (5) | 19 (100) |
| Infratentorial | 54 (96) | 42 (95) | 0 (0) |
| Drop metastases, n (%) | |||
| No | 45 (88) | 34 (97) | 15 (88) |
| Present at diagnosis | 2 (4) | 0 (0) | 0 (0) |
| During disease course | 4 (8) | 1 (3) | 2 (12) |
| No data | 5 | 9 | 2 |
| Disease progression (local recurrence/ metastases) | |||
| Events, n (%) | 21 (38) | 13 (31) | 6 (38) |
| No data | 1 | 2 | 3 |
| Death, n (%) | |||
| Events, n (%) | 7 (13) | 11 (28) | 2 (11) |
| Died of disease | 2 (4) | 1 (3) | 2 (11) |
| Perioperative complications | 1 (2) | 3 (8) | 0 (0) |
| Other reason | 1 (2) | 2 (5) | 0 (0) |
| No data | 3 | 5 | 0 |
| 5y-PFS-rates (%) | 64.5 | 67.4 | 60.3 |
| 10y-PFS-rates (%) | 41.8 | 45.3 | 60.3 |
| 5y-OS-rates (%) | 96.0 | 78.3 | 100.0 |
| 10y-OS-rates (%) | 83.2 | 67.5 | 75.0 |
Abbreviations: EPN-PFB = posterior fossa ependymoma group B, EPN-ZFTA = ZFTA fusion-positive ependymoma, KPS = Karnofsky performance status, OS = overall survival, PFS = progression-free survival, PF-SE/E = posterior fossa subependymoma molecular class with ependymoma histology, RT = radiotherapy.